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Summary
Unnatural oligomeric scaffolds designed to adopt
defined secondary structures (e.g., helices), while re-
taining the chemical diversity of amino acid side
chains, are of practical value to elaborate functional
mimetics of bioactive a-polypeptides. Enantiopure
N,N 0-linked oligoureas as short as seven residues
long have been previously shown to fold into a stable
helical structure, stabilized by 12- and 14-membered
H-bonded rings.We now report that eight-residue olig-
oureas designed to mimic globally amphiphilic a-heli-
cal host-defense peptides are effective against both
gram-negative and gram-positive bacteria (including
methicillin-resistant Staphylococcus aureus [MRSA])
and exhibit selectivity for bacterial versus mammalian
cells. Circular dichroism (CD) spectroscopy studies
suggest enhanced helical propensity of oligoureas in
the presence of phospholipid vesicles. The utility of
this new class of nonpeptidic foldamers for biological
applications is highlighted by high resistance to pro-
teolytic degradation.
Introduction
Antimicrobial a-peptides that adopt cationic amphipatic
structures (e.g., a helices) upon binding to cell mem-
branes (e.g., melittin from bee venom [1], magainins
from frog skin [2], cecropins from porcine small intestine
[3]) are ubiquitous in nature and represent important ef-
fector molecules of innate immunity [4]. They exhibit
narrow to broad spectrum of activity against gram-pos-
itive and/or gram-negative bacteria. Most importantly,
synthetic cationic peptides compared to conventional
*Correspondence: g.guichard@ibmc.u-strasbg.frantibiotics possess a low potential for the induction of
bacterial resistance [5, 6], which makes them attractive
candidates for the development of therapeutically useful
antimicrobial agents [4, 7].
Cationic antimicrobial peptides are believed to cause
cell death by a two-step mechanism involving interaction
with the lipid component of the membrane and mem-
brane permeabilization [8]. Several mechanisms for
membrane permeabilization have been postulated in-
cluding transient pore formation (‘‘barrel-stave model’’)
or detergent-like disruption of the membrane (‘‘carpet
model’’). The outer leaflet of the bacterial membrane is
essentially composed of lipids with negatively charged
phospholipid headgroups, whereas in plants and ani-
mals, it is almost zwitterionic and rich in cholesterol. As
a result, some cationic host-defense peptides, within
certain concentration limits, exhibit selectivity for bacte-
rial membranes versus human cells because of preferen-
tial electrostatic interactions. The lytic activity and mem-
brane selectivity of amphiphilic antimicrobial peptides
are strikingly dependent on properties such as helix sta-
bility, amphiphilicity (hydrophobic moment), hydropho-
bicity, relative width of the hydrophilic and hydrophobic
faces of the helix, as well as net charge. Structure activity
relationship studies remain challenging because se-
quence modifications of a-peptides generally affect sev-
eral parameters at the same time [9, 10].
Alternatively, the finding that unnatural oligoamide
backbones can adopt well-defined and controlled heli-
cal secondary structures suggested that one could use
them as scaffolds to distribute charged side chains in
a predictable manner for de novo design of cationic am-
phiphilic molecules mimicking natural host defense a-
peptides (for reviews see [11–13]). Antimicrobials based
on either b-peptides 314, 2.512, and 2.710,12 helical folds
[14–18] or on peptoids polyproline type I-like helix [19]
have been described. Yet, antimicrobial properties of
helix-forming peptidomimetics other than oligoamides
have not been documented.
N,N0-linked oligoureas A (also denoted PG-[b-
HXaau]n-NH2) with proteinogenic side chains are peptide
backbone mimetics that belong to theg-peptide lineage.
They are formally obtained by simple substitution of NH
for the aCH2 of the amino acid constituents of g
4-pep-
tides. We have shown recently, by using combination
of NMR spectroscopy and circular dichroism, that oligo-
ureas as short as seven residues can adopt a stable
right-handed 2.5-helical secondary structure stabilized
by 12- and 14-membered H-bonded rings (Figure 1A) in
varioussolventssuchaspyridine,methanol,andtrifluoro-
methanol [20–22] reminiscent of the helix described for
the corresponding g4-peptides. This strong helix folding
propensity, together with the diversity of available side
chain appendages and the expected resistance to pro-
tease degradation, make the oligourea backbone a
promising candidate for biomedical applications.
Herein, we report on the de novo design and syn-
thesis of short-chain amphiphilic cationic oligoureas
1–13 (Figure 1B) and evaluation of their antimicrobial
properties.
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(A) General formula of N,N0-linked oligoureas and schematic representation of the idealized (P)-2.512,14 helix (side view and top view) highlight-
ing the five residue repeat.
(B and C) Sequences and helical wheel representation of amphiphilic 2.5-helical oligoureas evaluated for antimicrobial activity. These oligour-
eas are exclusively composed of cationic side chains (b-HLysu, indicated by a plus sign) segregated on two-fifth (1–3, 5–13) or three-fifth (4) of
the helix circumference and hydrophobic aliphatic (indicated by a closed circle) and aromatic (indicated by a closed circle) side chains. A ter-
minal residue with a free amino group on the west side of the molecule is indicated by a plus sign and a closed circle or a plus sign and a closed
circle in a box, while an N-capped terminus is indicated by a closed circle or a closed circle in a box.Results and Discussion
Amphiphilic oligoureas 1–13, ranging from seven to nine
residue long were designed assuming an idealized 2.5-
helical structure as illustrated on Figure 1C. Cationic hy-
drophilic residues with side chain of lysine (b-HLysu)
were arranged to create a polar surface that roughly
covers two-fifth (1–3 and 5–13) or three-fifth (4) of the
helix circumference (Figure 1C). The remaining hydro-
phobic face was formed from a selection of residues
with aliphatic (Me, iPr, and iBu) and aromatic (Bn, 4-HO-
C6H4CH2,(1H-indol-3-yl)methyl) side chains. Oligoureas
1–13were synthesized on Rink amide resin withN-Fmoc
protected building blocks as previously described
[19, 23] and were purified to >95% homogeneity by C18
RP-HPLC. Although Fmoc/tBu chemistry on solid sup-
port is convenient and was previously found to be suit-
able for the synthesis of oligoureas with Ala, Val, Phe,
Tyr, and Lys side chains up to nonamers [20–23], it
showed some limitations in the course of the synthesis
of a number of oligoureas reported here, which were re-
covered in low yields after HPLC purifications. Recent
investigations with N-Boc protected monomers [24]have shown that Boc chemistry represents a useful al-
ternative to the preparation in high yields of amphiphilic
oligourea sequences incorporating functionalized side
chains (A.V., unpublished data).
In primary screening experiments (Table 1), antibacte-
rial activity was assayed against a representative set of
gram-positive (Staphylococcusaureus [S. aureus] Amer-
ican-type culture collection [ATCC] 25923) and gram-
negative (Escherichia coli [E. coli] ATCC 25922, Pseudo-
monas aeruginosa [P. aeruginosa] ATCC 27853) bacteria
cultured in brain-heart broth. Minimal inhibitory concen-
tration (MIC) as well as minimal bactericidal concentra-
tion (MBC) were determined after a 20 hr incubation at
35ºC in air. The a-helical a-peptide melittin from bee
venom [1] served as a positive control.
The first molecules examined in this study, namely
nonamers 1–4, had a comparable net charge but differed
in the composition of hydrophobic residues (b-HLeuu, b-
HPheu [1]; b-HAlau, b-HTyru [2]; b-HValu, b-HTyru [3]; b-
HValu, b-HTrpu [4]). Surprisingly, despite propensity for
helix formation in MeOH (monitored by CD at 203 nm)
(Figure 2A) [22] and amphiphilic character, none of these
molecules did show significant antibacterial activity
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533Table 1. Antimicrobial Activities Evaluated in Brain-Heart Broth
E. coli P. aeruginosa S. aureus
Compound MIC MBC MIC MBC MIC MBC
1 H-b-HLeuu-b-HLysu-b-HLeuu-b-HLysu-b-HPheu-b-HPheu-b-HLysu-b-HLeuu-b-HLysu >256 >256 >256 >256 >256 >256
2 H-b-HAlau-b-HLysu-b-HAlau-b-HLysu-b-HTyru-b-HTyru-b-HLysu-b-HAlau-b-Hlysu >256 >256 >256 >256 >256 >256
3 H-b-HTyru-b-HLysu-b-HValu-b-HLysu-b-HValu-b-HValu-b-HLysu-b-HValu-b-HLysu >256 >256 >256 >256 >256 >256
4 H-b-HValu-b-HLysu-b-HTrpu-b-HValu-b-HLysu-b-HValu-b-HLysu-b-HValu-b-HLysu 128 >256 >256 >256 >256 >256
5 H-b-HValu-b-HTrpu-b-HLysu-b-HTrpu-b-HLysu-b-HValu-b-HTrpu-b-HLysu >256 >256 >256 >256 256 >256
6 H-b-HValu-b-HLysu-b-HTrpu-b-HValu-b-HLysu-b-HTrpu-b-HLysu-b-HValu 32 128 128 >256 256 256
7 H-b-HValu-b-HLysu-b-HTrpu-b-HValu-b-HLysu-b-HValu-b-HLysu-b-HTrpu 32–64 64–128 128 >256 64 >256
8 H-b-HValu-b-HLysu-b-HPheu-b-HValu-b-HLysu-b-HPheu-b-HLysu-b-HValu 64–128 128 128 >256 64–128 >256
9 iPr-NHCO-b-HValu-b-HTrpu-b-HLysu-b-HTrpu-b-HLysu-b-HValu-b-HTrpu-b-HLysu 128 >256 >256 >256 128 256
10 iPr-NHCO-b-HValu-b-HLysu-b-HTrpu-b-HValu-b-HLysu-b-HTrpu-b-HLysu-b-HValu 32 256 64 >256 32 32
11 Bz-NHCO-b-HValu-b-HLysu-b-HTrpu-b-HValu-b-HLysu-b-HTrpu-b-HLysu-b-HValu 64 128 128 >256 32 64
12 iPr-NHCO-b-HLysu-b-HTrpu-b-HValu-b-HLysu-b-HTrpu-b-HLysu-b-HValu >256 >256 >256 >256 128 >256
13 iPr-NHCO-b-HValu-b-HLysu-b-HTrpu-b-HValu-b-HLysu-b-HTrpu-b-HLysu 64–128 64–256 256 >256 32–64 64–128
14 Ac-Val-Lys-Trp-Val-Lys-Trp-Lys-Val >256 >256 >256 >256 >256 >256
Melittin >256 >256 >256 >256 32 64
MIC and MBC in mg/ml.(Table 1). In aqueous environment, the shape of the CD
signal (one positive extremum at 203 nm) was con-
served, but its intensity was reduced, indicating a signif-
icantly lower propensity for helix formation in aqueous
environment (Figure 2F).
Shorter sequences (8-mers) with amphiphilic arrange-
ment of b-HLysu, b-HValu, and b-HTrpu residues (5–7)
were next evaluated. The rationale for choosing b-HValu
residues came from the finding that 3 exhibits a particu-larly intense CD signature in MeOH (per residue molar el-
lipticity at 203 nmw7 $ 104 deg $ cm2 $ dmol21) charac-
teristic of a stable 2.5-helical structure (Figure 2A).
Although valine is much less prone than alanine to a helix
formation, it has been shown recently that b-amino acid
residues bearing side chains branched at the first carbon
(e.g., b3-HVal) have a strong 314 helix propensity [25, 26].
The CD spectrum of3may suggest the same trend for 2.5
helix formation with b-HValu residues. Although theFigure 2. Helix-Forming Propensity of Oli-
goureas Investigated by Circular Dichroism
in Various Media at 0.5 mM $ per Residue
Molar Ellipticity in deg $ cm2 $ dmol21
(A) Closed square, molecule 3 in MeOH;
closed triangle, molecule 2 in MeOH.
(B) Closed square molecule 12 in MeOH;
closed triangle, molecule 13 in MeOH; open
square, molecule 12 in HBS; open triangle
molecule 13 in HBS (pH 7.4).
(C) Closed square, molecule 10 in MeOH;
closed triangle, molecule 6 in MeOH, open
square, molecule 10 in HBS (pH 7.4); open
triangle, molecule 6 in HBS (pH 7.4).
(D) X, molecule 10 in HBS (pH 7.4); closed tri-
angle, molecule 10 in zwitterionic liposomes
(PC/Chol, 80:20, lipid/oligomer ratio of 5);
closed square, molecule 10 in anionic lipo-
somes (PC/PG 70:30, lipid/oligomer ratio of
10).
(E) X, molecule 11 in HBS (pH 7.4); closed
square, molecule 11 in anionic liposomes
(PC/PG 70:30, lipid/oligomer ratio of 10).
(F) X, molecule 3 in HBS (pH 7.4); closed
square, molecule 3 in anionic liposomes
(PC/PG 70:30, lipid/oligomer ratio of 10).
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534Table 2. Antimicrobial Activities Evaluated in Mueller-Hinton Broth
E. coli P. aeruginosa S. aureus MRSA
Compound MIC MBC MIC MBC MIC MBC MIC MBC
10 iPr-NHCO-b-HValu-b-HLysu-b-HTrpu-b-HValu-b-HLysu-b-
HTrpu-b-HLysu-b-HValu
16 64 16 128 16 32 16 32
15 Cyclo((D)Arg-Arg-(D)Lys-Trp-(D)Leu-Trp-(D)Leu-Trp) 64 256 64 256 16 64 16 32
Melittin 32 64 64 256 8 32 8 64
MIC and MBC in mg/ml. MRSA: methicillin resistant Staphylococcus aureus.overall features of the N,N0-linked oligourea and b3-pep-
tide helices differ significantly, both helical backbones
are characterized by synclinal arrangement around
C(a)-C(b) bonds that may be stabilized when branched
side chains are present [27]. The (1H-indol-3-yl)methyl
side chain of b-HTrpu was preferred over other aromatic
hydrophobic side chains because of the known prefer-
ence of tryptophan residues for membrane surfaces
[28]. Tryptophan-rich sequence motifs are found in vari-
ous natural (e.g., indolicidin [29] lactoferricin [30]) as well
as in potent de novo designed [31, 32] antimicrobial pep-
tides. Although compound 5 was inactive, octamers 6
and 7 displayed significant antibacterial activity against
E. coli with a MIC of 32 mg/ml. Substitution of b-HPheu
for b-HTrpu residues in 6 to give 8, decreased the activity
against against E. coli and moderately improved activity
against S. aureus.
We have shown previously that the helix stability can
be significantly enhanced by acylating the free amino
terminus of oligoureas [22]. This effect is believed to re-
sult from the removal of the repulsive charge-pole inter-
action between the protonated amino group and the
positive pole of the helix, as well as from the presence
of one additional H-bond acceptor. The effect of cap-
ping on antibacterial activity was thus considered. Olig-
omers 9 and 10 N-capped with isopropyl isocyanate
were significantly more potent than their uncapped ho-
mologs 5 and 6, respectively (Table 1). Particularly note-
worthy is the pronounced inhibitory and bactericidal ef-
fect of compound 10 on S. aureus (MIC, 32 mg/ml; MBC,
32 mg/ml). Replacing the isopropyl urea terminus in 10by
a benzyl urea (11) only marginally affected the activity
against E. coli. Two analogs of 10 shorter by one residue
were synthesized by removing b-HValu at either termi-
nus of the oligomer. Interestingly, while removal of the
N-capped b-HValu residue (heptamer 12) was detrimen-
tal for the activity, this modification when conducted at
the opposite terminus to give heptamer 13, had little ef-
fect on antimicrobial potency. Although 12 and 13
strongly differ in their antibacterial activity, they exhibit
virtually identical CD spectra in MeOH and in HBS buffer
(10 mM HEPES, 150 mM NaCl, 3 mM EDTA [pH 7.4]) at
0.5 mM (Figure 2D).
An a-peptide (14) containing Lys, Trp, and Val resi-
dues arranged in the same order as in 10 was synthe-
sized and evaluated for comparison against the four
bacterial strains. This peptide did not show any signifi-
cant antibacterial activity (Table 1), thus suggesting
that the unique structure of the urea backbone contrib-
utes to the observed antibacterial activity of oligoureas.
This first screen revealed several trends. Antibacterial
activities of oligoureas appear to depend on a fine bal-
ance between cationic, aliphatic, and aromatic sidechains. The best results have been obtained when the
number of amino groups (terminus and side chains)
does not exceed 40% of the total number of side chains
and when aromatic side chains represent no more than
50% of hydrophobic side chains. In addition, capping
the free amino group of oligoureas appears to be a major
determinant of antibacterial activity of N,N0-linked olig-
oureas.
After this initial screening process, additional experi-
ments were conducted with 10. When compound 10
was assayed by dilution method in Mueller-Hinton broth
according to the National Committee for Clinical Labora-
tory Standards (NCCLS) guidelines, a significant gain in
activity was observed on gram-negative bacteria, with
MIC values of 16 mg/ml on E. coli and P. aeruginosa. Un-
der these conditions, MIC and MBC values of 16 and 32
mg/ml, respectively were obtained on S. aureus ATCC
25923andmethicillin-resistantS.aureus (MRSA) (Table2).
Interestingly, in vitro activity of octamer10against MRSA
was found to be equal to that of 15 (cyclo(D-Arg-Arg-D-
Lys-Trp-D-Leu-Trp-D-Leu-Trp), an eight-residue cyclic
D,L-a-peptide previously reported to be membrane ac-
tive and to protect mice against MRSA lethal infection
[33] (Table 2). The finding that 10 exhibits MICs and
MBCs in the same value range and is equally potent on
methicillin-sensitive and methicillin-resistant S. aureus
strains is particularly noteworthy and suggests that 10
may be acting by a mechanism involving membrane
permeation.
With the aim to correlate the antibacterial activity of 10
with its folding behavior, we have undertaken a series of
CD experiments. As expected, 10 showed a high helical
content in MeOH compared to uncapped 6 (3-fold in-
crease in intensity at 203 nm) (Figure 2C). The value of
the molar ellipticity per urea bond at 203 nm in MeOH
(ca 8 $ 104 deg $ cm2 $ dmol21) is the highest observed
so far for oligoureas (for comparison see [22]). Interest-
ingly, the same trend was observed in HBS buffer at pH
7.4, with no particular change in the overall shape of the
CD spectra (Figure 2C). However, the significantly
weaker molar ellipticity values per urea bond at 203
nm in this solvent (ca 2.5-fold decrease for both 6 and
10) were indicative of a lower propensity of oligoureas
for helix formation in aqueous environment (Figure 2C).
Changes in secondary structures that may occur upon
binding to lipids can be investigated with liposomes as
simplified model systems [34]. In the presence of nega-
tively charged PC/PG (70:30) small unilamellar vesicles
(SUV), the intensity of the maximum at 203 nm in the
CD spectrum of 10 recorded between 185 and 250 nm
experienced a sharp increase (ca 5 $ 104 deg $ cm2 $
dmol21) relative to aqueous solution, thus indicating
that the 2.5-helical conformation of 10 is stabilized in
Antimicrobial N,N 0-Linked Oligoureas
535the presence of bacterial membrane-mimetic lipid vesi-
cles (Figure 2D). A similar but attenuated behavior was
observed in the presence of zwitterionic (PC/Chol)
(80:20) lipid vesicles (Figure 2D). These data highlight
the differential ability of anionic and zwitterionic lipo-
somes to stabilize the 2.5-helical structure and might
suggest an increased specificity of 10 for anionic versus
zwitterionic membranes. The same trend was observed
for 11 (Figure 2E). In contrast, the intensity of the maxi-
mum at 203 nm measured in aqueous environment for
inactive nonamer 3 (Figure 2F) in the presence of anionic
lipid vesicles remained significantely lower. These re-
sults suggest that high 2.5-helix propensity in lipidic en-
vironment may be a precondition for oligoureas to be ac-
tive against bacteria.
Oligourea selectivity for prokaryotic cells was evalu-
ated by monitoring lysis of human red blood cells. The
hemolytic activity of molecule 10 compared to the corre-
sponding a-peptide 14, cyclo-D,L-a-peptide 15 and me-
littin is shown in Figure 3A. The concentration required
for 50% red blood cell lysis (HC50) together with selectiv-
ity values are reported in Table 3. While melittin is
strongly toxic toward red blood cells (HC50 = 30 mg/ml
in this assay), 10 exhibited significant selectivity for bac-
terial cells over human cells (selectivity value of 9.4 for
both E.coli and S. aureus). The hemolytic activity of 10
in this assay was found to be slightly lower than that
found for cyclic D,L-a-peptide 15, which exhibits selec-
Figure 3. Hemolytic Activity and Stability of Oligoureas toward Pro-
teolysis
(A) Hemolytic activity measured at indicated concentrations of Me-
littin (closed triangle), molecule 10 (open square), molecule 14
(closed square), and molecule 15 (closed circle).
(B) Proteolytic stability of molecule 13 evaluated by RP-HPLC after
5 days in mouse serum at 37ºC.tivity values of 3.1 and 6.3 for E. coli and S. aureus, re-
spectively. The corresponding inactive a-peptide 14
did not show any hemolytic activity.
The susceptibility of oligoureas to proteolytic cleav-
age was assessed by incubating octamer 13 in mouse
serum at 37ºC for different periods of time. After addition
of TFA and centrifugation, the supernatant was analyzed
by RP-HPLC. The area of the peak did not change signif-
icantly over a period of 5 days (Figure 3B), thus confirm-
ing the expected high resistance of oligoureas in serum.
Significance
In the field of biomimetic chemistry, several unnatural
oligoamide backbones (peptoids, b-peptides, g-pep-
tides) have been described that self-organize at the
molecular level to form stable helices useful to mimic
protein secondary structure elements. The predictabil-
ity of folding of these oligomeric strands led to the
development of molecules with function including
potent antibacterials [14–19] and inhibitors of protein-
protein interactions [35–37]. Although the amide bond
is undoubtedly a consensual motif for the elaboration
of peptidomimetic folding oligomers (‘‘foldamers’’),
we have shown that the urea moiety, by its capacity
to form autocomplementary and bidirectional hydro-
gen bonds can be substituted for the amide linkage
to generate oligomeric strands with strong propensity
for helix formation [20–22]. The present work is the
first attempt to design bioactive oligoureas based on
their propensity to adopt 2.5-helical structures. The
finding that cationic amphiphilic oligoureas as short
as 7–8 residues (e.g., 10) display significant antibacte-
rial activity in vitro as well as membrane selectivity is
promising. Like the a helix, the 2.512,14 helix of enantio-
pure N,N 0-linked oligoureas whose residues derive
from natural L-a amino acids is right handed and po-
larized. Assuming an ideal 2.5-helical structure and
a pitch of 5.1 A˚, octamer 10 is ca 16 A˚ long, which is
equivalent in size to a 11 residue a-peptide in a-helical
conformation. In comparison, the 26-residue melittin
is ca 40 A˚ longwhen it is in an a-helical structure. Inter-
estingly, while this paper was in preparation, Tew and
coworkers [38] reported that substituting ureas for am-
ides into antibacterial amphiphilic triarylamides [39]
resulted in more potent and more selective com-
pounds. This work further highlights the potential of
the urea backbone for the development of antimicro-
bial agents. Studies aimed at improving the potency,
the selectivity, as well as gaining further insight into
the antibacterial mechanisms of 2.5-helical oligoureas
are underway in our laboratories.
Table 3. Hemolytic Activity and Selectivity of Oligourea 10
Selectivity (HC50/MIC)
Compound HC50 E. coli S. aureus
Melittin 30 1.9 3.75
10 150 9.4 9.4
15 100 3.1 6.3
HC50 in mg/ml. MIC (in mg/ml) were those obtained in Mueller-Hinton
broth (see Table 2).
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General
Amino-acid derivatives were purchased from NeoMPS (Strasbourg,
France) and Rink amide resin from Senn Chemicals (Gentilly, France).
All other reagents and solvents were of analytical grade. Analytical
HPLC was performed by using a Varian apparatus on a Nucleosil
C18 (150 mm3 4.6 mm, 5 m particle column) by using a linear gradient
of A (0.1% TFA in H2O) and B (0.08% TFA in CH3CN) at a flow rate of
1.2 ml/min. Preparative reverse-phase HPLC were performed by us-
ing a Beckman apparatus on a Nucleodur C18 (250 mm3 10 mm, 16 m
particle column) by elution with a linear gradient of A (0.1% TFA in
H2O) and B (0.08% TFA in CH3CN), at a flow rate of 6 ml/min with
UV detection at 210 nm. Mass spectra were obtained by matrix-as-
sisted laser desorption/ionization mass spectrometry (MALDI-MS)
on a Protein TOF apparatus (Bruker Spectrospin, Bremen, Germany).
Oligoureas Synthesis and Purification
Oligoureas were prepared by Fmoc chemistry on a home made mul-
tichannel synthesizer with a semiautomatic mode on a 30–40 mmol
scale starting from Rink amide Resin (0.8 mmol/g). The Fmoc group
was removed with 25% piperidine in DMF (20 min) under nitrogen
bubbling. The resin was then filtered and washed with DMF (5 3 1
min). For each coupling step, a solution of succinimidyl carbamate
(five equiv.) in DMF was added on the resin, and the suspension
was mixed under periodic nitrogen bubbling for 120 min. Completion
of the coupling of the first carbamate building block was monitored
by a Kaiser ninhydrin test, and the remaining coupling steps were
performed in blind. A double coupling was performed systematically.
At the end of the synthesis, the resin was washed with CH2Cl2, Et2O,
and dried under nitrogen. Sidechain deprotection and cleavage of
the oligomers from the resin were performed simultaneously by
treatment with TFA/H2O/triisopropylsilane (95:2.5:2.5) for 150 min at
20ºC. The TFA solution were concentrated in vacuo, solubilized in
H2O/MeCN (9:1) and lyophilized to afford crude oligomers. The crude
oligomers were finally purified by RP-HPLC (linear gradient, 5%–65%
or 20%–80% B, 30 min) to a final purityR95% and lyophilized.
Oligomer 1
Purity of crude product 16% (C18 RP-HPLC). Yield after purification:
3 mg, 5%; white powder; RP-HPLC tR 15.6 min (linear gradient, 5%–
65% B, 20 min); MS (MALDI-TOF) m/z 1426.2 [M + H]+, 1446.5 [M +
Na]+, 1463.3 [M + K]+.
Oligomer 2
Purity of crude product 32% (C18 RP-HPLC). Yield after purification:
6 mg, 10%; white powder; RP-HPLC tR 9.8 min (linear gradient, 5%–
65% B, 20 min); MS (MALDI-TOF) m/z 1330.0 [M + H]+.
Oligomer 3
Purity of crude product 18% (C18 RP-HPLC). Yield after purification:
3 mg, 5%; white powder; RP-HPLC tR 12.1 min (linear gradient, 5%–
65% B, 20 min); MS (MALDI-TOF) m/z 1350.5 [M + H]+.
Oligomer 4
Purity of crude product 18% (C18 RP-HPLC). Yield after purification:
3 mg, 5%; white powder; RP-HPLC tR 13.9 min (linear gradient, 5%–
65% B, 20 min); MS (MALDI-TOF) m/z 1051.5 [M + H]+, 1073.3
[M + Na]+.
Oligomer 5
Purity of crude product 33% (C18 RP-HPLC). Yield after purification:
4 mg, 7%; white powder; RP-HPLC tR 13.7 min (linear gradient, 5%–
65% B, 20 min); MS (MALDI-TOF) m/z 1414.0 [M + Na]+, 1445.0
[M + K]+.
Oligomer 6
Purity of crude product 23% (C18 RP-HPLC). Yield after purification:
4 mg, 10%; white powder; RP-HPLC tR 14.4 min (linear gradient, 5%–
65% B, 20 min); MS (MALDI-TOF) m/z 1326.0 [M + Na]+, 1357.0
[M + K]+.
Oligomer 7
Purity of crude product 15% (C18 RP-HPLC). Yield after purification:
6mg, 9%; white powder; RP-HPLC tR 13.60 min (linear gradient, 5%–
65% B, 20 min); MS (MALDI-TOF) m/z 1305.1 [M + H]+, 1329.1
[M + K]+.
Oligomer 8
Purity of crude product 24% (C18 RP-HPLC). Yield after purification:
10mg, 15%; white powder; RP-HPLC tR 13.3 min (linear gradient,
5%–65% B, 20 min); MS (MALDI-TOF) m/z 1247.9 [M + Na]+.Oligomer 9
Purity of crude product 18% (C18 RP-HPLC). Yield after purification:
3 mg, 7%; white powder; RP-HPLC tR 17.4 min (linear gradient, 5%–
65% B, 20 min); MS (MALDI-TOF) m/z 1475.1 [M + H]+, 1496.5
[M + Na]+.
Oligomer 10
Purity of crude product 17% (C18 RP-HPLC). Yield after purification:
4 mg, 6%; white powder; RP-HPLC tR 11.4 min (linear gradient, 20%–
80% B, 20 min); MS (MALDI-TOF) m/z 1390.6 [M + H]+, 1414.4
[M + Na]+.
Oligomer 11
Purity of crude product 18% (C18 RP-HPLC). Yield after purification:
6 mg, 8%; white powder; RP-HPLC tR 11.6 min (linear gradient, 20%–
80% B, 20 min); MS (MALDI-TOF) m/z 1459.0 [M + Na]+.
Oligomer 12
Purity of crude product 18% (C18 RP-HPLC). Yield after purification:
10 mg, 16%; white powder; RP-HPLC tR 10.2 min (linear gradient,
20%–80% B, 20 min); MS (MALDI-TOF) m/z 1282.8 [M + Na]+.
Oligomer 13
Purity of crude product 21% (C18 RP-HPLC). Yield after purification:
7 mg, 11%; white powder; RP-HPLC tR 11.1 min (linear gradient,
20%–80% B, 20 min); MS (MALDI-TOF) m/z 1260.8 [M + H]+,
1282.8 [M + Na]+.
Preparation of Liposomes
The phospholipids egg yolk L-a-phosphatidylcholine (PC) and L-a-
phosphatidyl-DL-glycerol (PG) transesterified from egg yolk PC
were purchased from Sigma-Aldrich (Saint-Quentin-Fallavier,
France). Liposomes were prepared by mixing, in a round-bottom
flask, phospholipids (PC, PG) and cholesterol (PC/PG 70:30 and
PC/Cholesterol 80:20) in chloroform/methanol 9:1. After solvent
evaporation under high vacuum, the dried lipid film was hydrated
by Vortex mixing after addition of 1 ml HBS buffer (for 10 mmol lipids)
(10 mM HEPES, 150 mM NaCl, 3 mM EDTA [pH 7.4]). The resulting
suspensions were sonicated at 25ºC for 1 hr (5 s cycles interrupted
for 1.25 s) under a continuous flow of argon, with a 3 mm diameter
probe sonicator (Vibra Cell, Sonics and Material, Inc., Danbury,
CT) at 300 W. The SUV preparations were finally centrifuged for 10
min at 10,000 3 g to remove both the titanium dust originating
from the probe and the lipid aggregates. The size of the liposomes
was determined by dynamic light scattering with a Zeta-master
3000 instrument (Malvern Instruments, Paris, France). Data were
collected with the multimodal number distribution software included
in the instrument. All the formed vesicles were uniformly distributed
in size and exhibited average diameters of 100 nm (620 nm). The fi-
nal lipid concentration of the liposomal suspensions was deter-
mined by enzymatic titration of phosphatidyl choline (phospholipid
B test WACO COF was purchased from OXOID [Dardilly, France]).
All the liposomal formulations were freshly prepared before use.
Circular Dichroism
All circular dichroism (CD) spectra were recorded on a J-810 Jasco
spectropolarimeter 150S (Jasco France, Nantes, France). Data are
expressed in term of mean-residue ellipticity in deg $ cm2 $
dmol21, calculated per mol of urea groups present. CD spectra of
oligomers (0.5 mM) were aquired in MeOH and in HBS buffer (10
mM HEPES, 150 mMNaCl, 3 mM EDTA [pH 7.4]) at 25ºC, between
190 and 250 nm by using a quartz cylindrical cell with a path length
of 0.05 mm (Hellma 121-QS-0.05, Paris, France). Experiments in
presence of liposomes were conducted with a ratio lipid/oligomer
of five for zwitterionic formulation (PC/Cholesterol 80:20) and ten
for anionic formulation (PC/PG 70:30), the concentration of oligomer
remaining 0.5 mM. Minor contributions of circular differential scat-
tering by liposomes were eliminated by substraction of the CD spec-
trum of liposomes alone.
In Vitro Susceptibility of Aerobic Bacteria
Four strains were selected: Escherichia coli ATCC 25922, Staphylo-
coccus aureus ATCC 25923, Pseudomonas aeruginosa ATCC
27853, and a clinical isolated methicillin resistant Staphylococcus
aureus strain. Antibacterial activity of the molecules was tested by
dilution method in Brain-Heart broth (BioRad, Marnes-la-Coquette)
or in Mueller-Hinton broth (Difco, Becton-Dickinson France, Le
Pont de Claix) in order to determine the minimal inhibitory
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537concentration (MIC) and the minimal bactericidal concentration
(MBC). Stock solutions were obtained by solubilizing molecule pow-
ders in sterile distillated water at concentration of 2.56 mg/ml and
serial 2-fold diluted solutions were prepared. Bacterial inoculum
was standardized by using direct suspensions of colonies from
overnight growth in saline adjusted to a turbidity matching that of
a 0.5 McFarland standard, (108 CFU/ml) and diluted to obtain a den-
sity comprised between 105 CFU/ml and 107 CFU/ml. Tubes con-
taining 900 ml of inoculum with 100 ml of molecules solutions were in-
cubated in air at 35ºC for 18 to 20 hr before the MICs were
determined. Purity and inoculum density as well as percentage of vi-
able bacteria in limpid tubes were checked by plate counting on
sheep blood agar. Broth without any molecule solution was inocu-
lated with each selected bacterial strain as a control for organism vi-
ability (growth control). The susceptibility of S. aureus strains
against a glycopeptide (vancomycin) was used as an internal control
as well as the activity of melittin.
In Vitro Hemolysis Assay
Human blood collected on heparin was centrifuged at 1,000 3 g for
10 min to remove serum. Red blood cells were then washed three
times with 0.9% saline solution and resuspended to a concentration
of 5% in saline solution containing 10% FBS (v/v). Red blood cells
were then incubated with serial dilution of the molecules at 37ºC
for 1 hr. Control samples included a saline solution as negative con-
trol and 1% Triton X-100 for 100% hemolysis. For measurement of
hemoglobin content, plates were centrifuged at 1,000 3 g for 5
min, and aliquots of the supernatant were read at 570 nm.
Proteolytic Degradation
Oligomer 10 (1 mg/ml in PBS) was incubated at 37ºC with the same
volume of BALB/c serum freshly collected. For analysis, 50 ml of so-
lution was collected, and 5 ml of TFA was added to precipitate serum
proteins. After addition of 200 ml of PBS buffer, solutions were cen-
trifugated for 15 min. Supernatants were diluted twice and analyzed
by RP-HPLC. (C18 column, linear gradient, 20%–80% B, 20 min.)
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